dCE-2

dCE-2 exhibits moderate binary binding affinity (K_D = 1300 nM) for purified CBP-BRD in a cell-free BROMOscan competition assay, while no detectable binding activity is observed for purified EP300-BRD^[1].
dCE-2 exhibits moderate binary binding to purified CBP-BRD (IC₅₀ = 150 nM); in a cell-free TR-FRET competition assay, its binding is enhanced (IC₅₀ = 45 nM) with positive cooperativity (α = 3.4)^[1] in the presence of purified CRBN.
dCE-2 (0.01-5 μM; 2-24 h) potently degrades CBP (DC₅₀ = 40 nM) and EP300 in LP1 multiple myeloma cells via the PROTAC mechanism, with the maximum degradation effect observed after 16-24 h of treatment^[1].
dCE-2 (1 μM; 16 h) degrades CBP in MM1S, LNCaP and SH-SY5Y cancer cell lines, with a sustained bias toward EP300^[1].
dCE-2 (0.001-10 μM) inhibits the proliferation of multiple myeloma cell lines LP1 (GI₅₀ = 1.5 μM) and MM1S (GI₅₀ = 35 nM)^[1].
dCE-2 (1 μM; 16 h) downregulates CBP, EP300 and MYC (but not BRD4) in LP1 and MM1S cells, as determined by global proteomic analysis^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.